Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Prim. 3, 17046 (2017).
Google Scholar
Madduri, D., Dhodapkar, M. V., Lonial, S., Jagannath, S. & Cho, H. J. SOHO state of the art updates and next questions: T-cell-directed immune therapies for multiple myeloma: chimeric antigen receptor-modified T cells and bispecific T-cell-engaging agents. Clin. Lymphoma Myeloma Leuk. 19, 537–544 (2019).
Google Scholar
Shah, N., Chari, A., Scott, E., Mezzi, K. & Usmani, S. Z. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 34, 985–1005 (2020).
Shah, U. A. & Mailankody, S. Emerging immunotherapies in multiple myeloma. Brit. Med. J. 370, m3176 (2020).
Google Scholar
Bu, D. X. et al. Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget 9, 25764–25780 (2018).
Google Scholar
Carpenter, R. O. et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19, 2048–2060 (2013).
Google Scholar
Khattar, P. et al. B-cell maturation antigen is exclusively expressed in a wide range of B-cell and plasma cell neoplasm and in a potential therapeutic target for BCMA directed therapies. Blood 130, 2755–2755 (2017).
Sanchez, E. et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br. J. Haematol. 158, 727–738 (2012).
Google Scholar
Sanchez, E. et al. Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma. Clin. Cancer Res. 22, 3383–3397 (2016).
Google Scholar
Tai, Y. T. et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood 127, 3225–3236 (2016).
Google Scholar
Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021).
Google Scholar
Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726–1737 (2019).
Google Scholar
Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 398, 314–324 (2021).
Google Scholar
Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transpl. 25, 625–638 (2019).
Google Scholar
Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47–62 (2018).
Google Scholar
Gagelmann, N., Ayuk, F., Atanackovic, D. & Kroger, N. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: a meta-analysis. Eur. J. Haematol. 104, 318–327 (2020).
Google Scholar
Jatiani, S. S. et al. Myeloma CAR-T CRS management with IL-1R antagonist anakinra. Clin. Lymphoma Myeloma Leuk. 20, 632–636 (2020).
Google Scholar
Hawrylycz, M. J. et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 489, 391–399 (2012).
Google Scholar
Lee, L. et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br. J. Haematol. 174, 911–922 (2016).
Google Scholar
Shah, U. A. & Mailankody, S. CAR T and CAR NK cells in multiple myeloma: expanding the targets. Best Pract. Res. Clin. Haematol. 33, 101141 (2020).
Kotecha, N., Krutzik, P. O. & Irish, J. M. Web-based analysis and publication of flow cytometry experiments. Curr. Protoc. Cytom. Chapter 10, Unit10.17 (2010).
Kolde, R. pheatmap: Pretty Heatmaps. Version 1.0.12. https://rdrr.io/cran/pheatmap/ (2019).
Wickham, H. ggplot2: Elegant Graphics for Data Analysis, (Springer-Verlag, 2016).
Zunder, E. R. et al. Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm. Nat. Protoc. 10, 316–333 (2015).
Google Scholar
Nowicka, M. et al. CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets. F1000Res 6, 748 (2017).
Google Scholar
Weber, L. M. diffcyt: Differential discovery in high-dimensional cytometry via high-resolution clustering. Commun. Biol. 2, 183 (2019).
Crowell, H. L., Zanotelli, V. R. T., Chevrier, S. & Robinson, M. D. CATALYST: Cytometry dATa anALYSis Tools. https://github.com/HelenaLC/CATALYST (2020).
Ellis, B. et al. flowCore: basic structures for flow cytometry data. https://www.bioconductor.org/packages/devel/bioc/manuals/flowCore/man/flowCore.pdf (2019).
Van Gassen, S. et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A 87, 636–645 (2015).
Google Scholar
Kim, H. J., Lin, Y., Geddes, T. A., Yang, J. Y. H. & Yang, P. CiteFuse enables multi-modal analysis of CITE-seq data. Bioinformatics 36, 4137–4143 (2020).
Amezquita, R. A. et al. Orchestrating single-cell analysis with Bioconductor. Nat. Methods 17, 137–145 (2019).
